Cargando…
Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695104/ https://www.ncbi.nlm.nih.gov/pubmed/36423123 http://dx.doi.org/10.3390/v14112514 |
_version_ | 1784837973617934336 |
---|---|
author | Bruno, Giuseppe Giotta, Massimo Perelli, Serena De Vita, Giuseppina Bartolomeo, Nicola Buccoliero, Giovanni Battista |
author_facet | Bruno, Giuseppe Giotta, Massimo Perelli, Serena De Vita, Giuseppina Bartolomeo, Nicola Buccoliero, Giovanni Battista |
author_sort | Bruno, Giuseppe |
collection | PubMed |
description | Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the era of Omicron and sub-variants. Methods: Our retrospective study aimed to compare the safety profile and effectiveness of the two antivirals in all consecutive high-risk outpatients between 11 January and 10 July 2022. A logistic regression model was carried out to assess factors associated with the composite outcome defined as all-cause hospitalization and/or death at 30 days. Results: A total of 719 individuals were included: 554 (77%) received Molnupiravir, whereas 165 (23%) were NMV-r users. Overall, 43 all-cause hospitalizations (5.9%) and 13 (1.8%) deaths were observed at 30 days. A composite outcome occurred in 47 (6.5%) individuals. At multivariate analysis, male sex [OR 3.785; p = 0.0021], age ≥ 75 [OR 2.647; p = 0.0124], moderate illness [OR 16.75; p < 0.001], and treatment discontinuation after medical decision [OR 8.148; p = 0.0123] remained independently associated with the composite outcome. Conclusions: No differences between the two antivirals were observed. In this real-life setting, the early use of both of the oral antivirals helped limit composite outcome at 30 days among subjects who were at high risk of disease progression. |
format | Online Article Text |
id | pubmed-9695104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96951042022-11-26 Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 Bruno, Giuseppe Giotta, Massimo Perelli, Serena De Vita, Giuseppina Bartolomeo, Nicola Buccoliero, Giovanni Battista Viruses Article Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the era of Omicron and sub-variants. Methods: Our retrospective study aimed to compare the safety profile and effectiveness of the two antivirals in all consecutive high-risk outpatients between 11 January and 10 July 2022. A logistic regression model was carried out to assess factors associated with the composite outcome defined as all-cause hospitalization and/or death at 30 days. Results: A total of 719 individuals were included: 554 (77%) received Molnupiravir, whereas 165 (23%) were NMV-r users. Overall, 43 all-cause hospitalizations (5.9%) and 13 (1.8%) deaths were observed at 30 days. A composite outcome occurred in 47 (6.5%) individuals. At multivariate analysis, male sex [OR 3.785; p = 0.0021], age ≥ 75 [OR 2.647; p = 0.0124], moderate illness [OR 16.75; p < 0.001], and treatment discontinuation after medical decision [OR 8.148; p = 0.0123] remained independently associated with the composite outcome. Conclusions: No differences between the two antivirals were observed. In this real-life setting, the early use of both of the oral antivirals helped limit composite outcome at 30 days among subjects who were at high risk of disease progression. MDPI 2022-11-14 /pmc/articles/PMC9695104/ /pubmed/36423123 http://dx.doi.org/10.3390/v14112514 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bruno, Giuseppe Giotta, Massimo Perelli, Serena De Vita, Giuseppina Bartolomeo, Nicola Buccoliero, Giovanni Battista Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title | Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title_full | Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title_fullStr | Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title_full_unstemmed | Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title_short | Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19 |
title_sort | early access to oral antivirals in high-risk outpatients: good weapons to fight covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695104/ https://www.ncbi.nlm.nih.gov/pubmed/36423123 http://dx.doi.org/10.3390/v14112514 |
work_keys_str_mv | AT brunogiuseppe earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 AT giottamassimo earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 AT perelliserena earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 AT devitagiuseppina earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 AT bartolomeonicola earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 AT buccolierogiovannibattista earlyaccesstooralantiviralsinhighriskoutpatientsgoodweaponstofightcovid19 |